EQS-Adhoc: MeVis Medical Solutions AG: Forecast adjustment for the 2024/2025 fiscal year
|
EQS-Ad-hoc: MeVis Medical Solutions AG / Key word(s): Change in Forecast Bremen, August 21, 2025 – MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, is adjusting its forecast for the current fiscal year based on preliminary figures for the first ten months. For fiscal year 2024/2025 (October 1, 2024 to September 30, 2025), revenue is now expected to decline slightly to between €16.5 million and €17.0 million (previous forecast: €17.0 million to €17.5 million). MeVis expects EBIT (earnings before interest and taxes) to decline to between €3.0 million and €3.5 million (previous forecast: €3.5 million to €4.0 million). License sales are below expectations and cannot be offset by maintenance revenues and other revenues. ************************************************************************ Contact: Kirchhoff, Marcus / CEO End of Inside Information
21-Aug-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | MeVis Medical Solutions AG |
| Caroline-Herschel-Str. 1 | |
| 28359 Bremen | |
| Germany | |
| Phone: | +49 421 224 95 0 |
| Fax: | +49 421 224 95 999 |
| E-mail: | ir@mevis.de |
| Internet: | http://www.mevis.de |
| ISIN: | DE000A0LBFE4 |
| WKN: | A0LBFE |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2187294 |
| End of Announcement | EQS News Service |
|
|
2187294 21-Aug-2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 18,07 | 17,13 | 16,21 | 18,76 | 17,34 | 16,97 | 16,80 | |
| EBITDA1,2 | 8,25 | 5,97 | 4,77 | 7,99 | 3,99 | 3,63 | 3,35 | |
| EBITDA-Margin3 | 45,66 | 34,85 | 29,43 | 42,59 | 23,01 | 21,39 | 19,94 | |
| EBIT1,4 | 8,00 | 5,81 | 4,64 | 7,90 | 3,89 | 3,50 | 3,20 | |
| EBIT-Margin5 | 44,27 | 33,92 | 28,62 | 42,11 | 22,43 | 20,63 | 19,05 | |
| Net Profit (Loss)1 | 8,07 | 5,70 | 4,55 | 7,79 | 4,92 | 4,56 | 4,40 | |
| Net-Margin6 | 44,66 | 33,28 | 28,07 | 41,53 | 28,37 | 26,87 | 26,19 | |
| Cashflow1,7 | 6,55 | 2,89 | 9,13 | 4,86 | 5,85 | 3,15 | 0,00 | |
| Earnings per share8 | 4,43 | 3,13 | 2,50 | 4,28 | 2,70 | 3,15 | 2,40 | |
| Dividend per share8 | 0,95 | 0,95 | 0,95 | 0,95 | 0,95 | 0,95 | 0,95 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Deloitte
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| MeVis Med. Solutions | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A0LBFE | DE000A0LBFE4 | AG | 45,14 Mio € | 16.11.2007 | Halten | 9F5C4V35+HX |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 10,12 | 10,65 | 0,95 | 7,99 | 2,53 | 14,35 | 2,66 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,95 | 0,95 | 0,95 | 3,83% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 25.03.2025 | - | 27.05.2025 | - | 30.01.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -1,03% | -1,72% | -1,59% | +0,00% | -54,91% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
